Crohn's Disease

M14-115

A Multicenter, Randomized, Double-Blind Study to Evaluate Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Crohn’s Disease and Evidence of Mucosal Ulceration. (AbbVie M14-115)

This is a phase 3 research study for patients with moderately to severely active Crohn’s disease aged 18- 75 years old. Participants will remain on the study and continue to receive the study investigational medication and/or placebo until the study is completed unless they are removed or voluntarily end participation. It is estimated that patients will participate for a minimum of 1 year. During this time, participants will be evaluated by the study team at varying 2-6 week intervals. 

 

Vedolizumab-4006

An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy with Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects with Crohn’s Disease Stratified at Higher Risk for Developing Complications (Takeda Vedolizumab-4006).

This is a phase 4 research study for patients with newly diagnosed with Crohn’s disease within the last 24 months, aged 18-80 years old. Participants will remain on the study and continue to receive the study investigational medication and until the study is completed unless they are Early Discontinued or voluntarily end participation. It is estimated that patients will participate for a minimum of approximately 2 years. During this time, participants will be evaluated by the study team every 2-4 weeks for up to 128 weeks. 

 

A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects with Active Crohn’s Disease (SERENITY) I6T-MC-AMAG

This is a phase 2 research study for patients with active Crohn’s disease age 18 years and older. Participants will remain on the study and continue to receive the study investigational medication and/or placebo until the study is completed unless they are removed or voluntarily end participation. It is estimated that patients will participate for a minimum of 2 years. During this time, participants will be evaluated by the study team approximately every 2-4 weeks.

For more information or eligibility criteria, call our Research Hotline number at 612-870-5599, OR input the following information and we will follow up with you to discuss your interest:

ATTENTION: This form is not meant for transmitting medical, prescription or appointment information or to initiate direct communications with our health care providers. Calls of this nature will not be answered by email and should be directed to 612-871-1145. In the event of a medical emergency, dial 911. Emails are monitored Monday through Friday during regular business hours.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.